Pregled bibliografske jedinice broj: 704940
WARFARIN: GOLD STANDARD OF ANTICOAGULANT THERAPY
WARFARIN: GOLD STANDARD OF ANTICOAGULANT THERAPY // Acta Clinica Croatica 53 (Suppl 1)
Pula, Hrvatska, 2014. (pozvano predavanje, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 704940 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
WARFARIN: GOLD STANDARD OF ANTICOAGULANT THERAPY
Autori
Budinčević, Hrvoje
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Acta Clinica Croatica 53 (Suppl 1)
/ - , 2014
Skup
54th International Neuropsychiatric Pula Congress
Mjesto i datum
Pula, Hrvatska, 18.06.2014. - 21.06.2014
Vrsta sudjelovanja
Pozvano predavanje
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
warfarin
Sažetak
Antithrombotic therapy is recommended for ischemic stroke prevention. Anticoagulants are most commonly used as a long term oral therapy in patients with atrial fibrillation or other cardiac condition with a high risk of embolism. Since 1950s oral anticoagulant therapy with vitamin K antagonists (warfarin) was introduced into clinical practice, and it is has been a gold standard for secondary prevention of ischemic stroke. In the last few years its role in stroke prevention in patients with nonvalvular atrial fibrillation has been weakened because of development and presence of novel oral anticoagulants (direct thrombin inhibitors and direct inhibitors of factor Xa). However, warfarin has still a leading role in stroke prevention and treatment in patients with valvular atrial fibrillation, atrial fibrillation and severe renal impairment, acute myocardial infarction with mural thrombus, cerebral venous thrombosis and acquired or inherited hypercoagulability states. The advantages, disadvantages and other indications for treatment with warfarin will be discussed.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
Citiraj ovu publikaciju:
Časopis indeksira:
- Scopus
- MEDLINE